Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists: Treatment of diabetic maculopathy (as of April, 2013);Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Therapie der diabetischen Makulopathie (Stand April 2013)

Klinische Monatsblatter fur Augenheilkunde

Volumn 230, Issue 6, 2013, Pages 614-628

  Ziemssen, F ^a   Helbig, H ^b   Lemmen, K D ^b   Spital, G ^b   Bertram, B ^b   Hillenkamp, J ^b   Bartz Schmidt, K U ^b   Bornfeld, N ^b   Bresgen, M ^b   Eter, N ^b   Friedrichs, W ^b   Heimann, H ^b   Hoerauf, H ^b   Holz, F G ^b   Kampik, A ^b   Kirchhof, B ^b   Pauleikhoff, D ^b   Roider, J ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIABETIC RETINOPATHY; RETINA MACULOPATHY;

ANTI-INFLAMMATORY AGENTS; DIABETIC RETINOPATHY; GERMANY; HUMANS; LASER COAGULATION; OPHTHALMOLOGY;

EID: 84879528703     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0032-1328663     Document Type: Article

References (103)

1. Robert-Koch-Institut DEGS - Studie zur Gesundheit Erwachsener in Deutschland. Im Internet: http://www.degs-studie.de/ Stand: 01.12.2012
2. Brinks R., Tamayo T., Kowall B. et al. Prevalence of type 2 diabetes in Germany in 2040: estimates from an epidemiological model. Eur J Epidemiol: 2012; 27 791 797
3. DOG RB Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie der diabetischen Makulopathie. Ophthalmologe: 2011; 108 485 500
4. DOG RB Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie der diabetischen Makulopathie. Klin Monbl Augenheilkd: 2011; 228 446 459
5. Nguyen Q. D., Brown D. M., Marcus D. M. et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology: 2012; 119 789 801
6. Rajendram R., Fraser-Bell S., Kaines A. et al. A 2-year prospective randomized controlled trial of intravitreal Bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol: 2012; 130 972 979
7. Aiello L. P., Beck R. W., Bressler N. M. et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology: 2011; 118 e5-14
8. Mitchell P., Bandello F., Schmidt-Erfurth U. et al. and RESTORE Study Group The RESTORE study ranibizumab Monotherapy or combined with Laser versus laser monotherapy for diabetic macular edema. Ophtalmology: 2011; 118 615 625
9. Patel R. D., Messner L. V., Teitelbaum B. et al. Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol: 2013; 155 1038 1044
10. Maheshwary A. S., Oster S. F., Yuson R. M. et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol: 2010; 150 63 67
11. Murakami T., Nishijima K., Akagi T. et al. Optical coherence tomographic reflectivity of photoreceptors beneath cystoid spaces in diabetic macular edema. Invest Ophthalmol Vis Sci: 2012; 53 1506 1511
12. Otani T., Yamaguchi Y., Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina: 2010; 30 774 780
13. Yohannan J., Bittencourt M., Sepah Y. J. et al. Association of retinal sensitivity to integrity of photoreceptor inner/outer segment junction in patients with diabetic macular edema. Ophthalmology: 2013; [in press]
14. Lee D. H., Kim J. T., Jung D. W. et al. The relationship between foveal ischemia and spectral-domain optical coherence tomography findings in ischemic diabetic macular edema. Invest Ophthalmol Vis Sci: 2013; 54 1080 1085
15. Bressler N. M., Miller K. M., Beck R. W. et al. Observational study of subclinical diabetic macular edema. Eye (Lond): 2012; 26 833 840
16. Jittpoonkuson T., Garcia P. M., Rosen R. B. Correlation between fluorescein angiography and spectral-domain optical coherence tomography in the diagnosis of cystoid macular edema. Br J Ophthalmol: 2010; 94 1197 1200
17. Podoleanu A. G., Rosen R. B. Combinations of techniques in imaging the retina with high resolution. Prog Retin Eye Res: 2008; 27 464 499
18. He L., Chan A., Leng T. et al. Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy. Clin Ophthalmol: 2011; 5 1751 1758
19. Bolz M., Kriechbaum K., Simader C. et al. In vivo retinal morphology after grid laser treatment in diabetic macular edema. Ophthalmology: 2010; 117 538 544
20. Tan C. S., Ngo W. K., Chew M. C. et al. Diurnal variation of retinal thickness measured by optical coherence tomography in normal adults. Invest Ophthalmol Vis Sci: 2012; 53 1639 1640
21. Kotsidis S. T., Lake S. S., Alexandridis A. D. et al. 24-Hour variation of optical coherence tomography-measured retinal thickness in diabetic macular edema. Eur J Ophthalmol: 2012; 22 785 791
22. Chalam K. V., Bressler S. B., Edwards A. R. et al. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg spectralis optical coherence tomography. Invest Ophthalmol Vis Sci: 2012; 53 8154 8161
23. Khurana R. N., Dupas B., Bressler N. M. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology: 2010; 117 1376 1380
24. Byeon S. H., Chu Y. K., Hong Y. T. et al. New insights into the pathoanatomy of diabetic macular edema: angiographic patterns and optical coherence tomography 60. Retina: 2012; 32 1087 1099
25. Murakami T., Nishijima K., Sakamoto A. et al. Foveal cystoid spaces are associated with enlarged foveal avascular zone and microaneurysms in diabetic macular edema. Ophthalmology: 2011; 118 359 367
26. Ota M., Nishijima K., Sakamoto A. et al. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology: 2010; 117 1996 2002
27. Framme C., Schweizer P., Imesch M. et al. Behaviour of SD-OCT detected hyperreflective foci in the retina of Anti-VEGF treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci: 2012; 53 5814 5818
28. Lee S. N., Chhablani J., Chan C. K. et al. Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema. Am J Ophthalmol: 2013; 155 905 912
29. Esmaeelpour M., Povazay B., Hermann B. et al. Mapping choroidal and retinal thickness variation in type 2 diabetes using three-dimensional 1060-nm optical coherence tomography. Invest Ophthalmol Vis Sci: 2011; 52 5311 5316
30. Weinberger D., Kramer M., Priel E. et al. Indocyanine green angiographic findings in nonproliferative diabetic retinopathy. Am J Ophthalmol: 1998; 126 238 247 (Pubitemid 28397097)
31. Sadda S. R., Keane P. A., Ouyang Y. et al. Impact of scanning density on measurements from spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci: 2010; 51 1071 1078
32. Ueda T., Nawa Y., Hara Y. Relationship between the retinal thickness of the macula and the difference in axial length. Graefes Arch Clin Exp Ophthalmol: 2006; 244 498 501
33. Sonmez B., Bozkurt B., Atmaca A. et al. Effect of glycemic control on refractive changes in diabetic patients with hyperglycemia. Cornea: 2005; 24 531 537 (Pubitemid 40885029)
34. Tai M. C., Lin S. Y., Chen J. T. et al. Sweet hyperopia: refractive changes in acute hyperglycemia. Eur J Ophthalmol: 2006; 16 663 666
35. Okamoto F., Sone H., Nonoyama T. et al. Refractive changes in diabetic patients during intensive glycaemic control. Br J Ophthalmol: 2000; 84 1097 1102
36. Gwinup G., Villarreal A. Relationship of serum glucose concentration to changes in refraction. Diabetes: 1976; 25 29 31
37. Sun J. K., Qin H., Aiello L. P. et al. Evaluation of visual acuity measurements after autorefraction vs. manual refraction in eyes with and without diabetic macular edema. Arch Ophthalmol: 2012; 130 470 479
38. Sun J. K., Aiello L. P., Cavallerano J. D. et al. Visual acuity testing using autorefraction or pinhole occluder compared with a manual protocol refraction in individuals with diabetes. Ophthalmology: 2011; 118 537 542
39. Ferris F. L. III, Kassoff A., Bresnick G. H. et al. New visual acuity charts for clinical research. Am J Ophthalmol: 1982; 94 91 96 (Pubitemid 12080556)
40. Kaiser P. K. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc: 2009; 107 311 324
41. Ip M. S., Domalpally A., Hopkins J. J. et al. Long-term effects of Ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol: 2012; 130 1145 1152
42. Bressler S. B., Qin H., Beck R. W. et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol: 2012; 130 1153 1161
43. Michaelides M., Kaines A., Hamilton R. D. et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology: 2010; 117 1078 1086
44. Ramachandran A., Snehalatha C., Sasikala R. et al. Vascular complications in young Asian Indian patients with type 1 diabetes mellitus. Diabetes Res Clin Pract: 2000; 48 51 56 (Pubitemid 30125829)
45. Michaelides M., Fraser-Bell S., Hamilton R. et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina: 2010; 30 781 786
46. Soheilian M., Ramezani A., Obudi A. et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology: 2009; 116 1142 1150
47. Shimura M., Yasuda K., Yasuda M. et al. Visual outcome after intravitreal bevacizumab depends on the OCT patterns of patients with diffuse diabetic macular edema. Retina: 2013; 33 740 747
48. Dolgin E. In vision trial, some researchers would rather see double. Nat Med: 2010; 16 611
49. Goyal S., Lavalley M., Subramanian M. L. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol: 2011; 249 15 27
50. Parravano M., Menchini F., Virgili G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev: 2009; CD007419
51. Ford J. A., Elders A., Shyangdan D. et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ: 2012; 345 e5182
52. Davidovic S. P., Nikolic S. V., Curic N. J. et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy 1. Eur J Ophthalmol: 2012; 22 792 798
53. Fortin P., Mintzes B., Innes M. A systematic review of intravitreal bevacizumab for the treatment of diabetic macular edema. CADTH Technol Overv: 2013; 3 e3203
54. Do D. V., Nguyen Q. D., Boyer D. et al. One-year outcomes of the DA VINCI Study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology: 2012; 119 1658 1665
55. Do D. V., Nguyen Q. D., Shah S. M. et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol: 2009; 93 144 149
56. Sultan M. B., Zhou D., Loftus J. et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology: 2011; 118 1107 1118
57. Dombi T., Kwok K. K., Sultan M. B. A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus. BMC Ophthalmol: 2012; 12 37
58. Bhavsar A. R., Googe J. M. Jr., Stockdale C. R. et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol: 2009; 127 1581 1583
59. Bhavsar A. R., Stockdale C. R., Ferris FL I. II et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol: 2012; 130 809 810
60. Schachat A. P., Rosenfeld P. J., Liesegang T. J. et al. Endophthalmitis is not a "never evento" Ophthalmology: 2012; 119 1507 1508
61. Jaissle G. B., Szurman P., Bartz-Schmidt K. U. Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monbl Augenheilkd: 2005; 222 390 395 (Pubitemid 40825853)
62. Wykoff C. C., Flynn H. W. Jr., Rosenfeld P. J. Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol: 2011; 152 717 719
63. Doshi R. R., Leng T., Fung A. E. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina: 2012; 32 473 476
64. Abell R. G., Kerr N. M., Allen P. et al. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol: 2012; 96 1474 1478
65. Simunovic M. P., Rush R. B., Hunyor A. P. et al. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol: 2012; 96 1350
66. Elman M. J., Bressler N. M., Qin H. et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology: 2011; 118 609 614
67. Elman M. J., Aiello L. P., Beck R. W. et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology: 2010; 117 1064 1077
68. Chakravarthy U., Harding S. P., Rogers C. A. et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology: 2012; 119 1399 1411
69. Martin D. F., Maguire M. G., Fine S. L. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology: 2012; 119 1388 1398
70. Zhang W., Liu H., Rojas M. et al. Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy: 2011; 3 609 628
71. Zhang Y., Ma J., Meng N. et al. Comparison of intravitreal triamcinolone acetonide with intravitreal bevacizumab for treatment of diabetic macular edema: a meta-analysis. Curr Eye Res: 2013; 38 578 587
72. Haller J. A., Kuppermann B. D., Blumenkranz M. S. et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol: 2010; 128 289 296
73. Zucchiatti I., Lattanzio R., Querques G. et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica: 2012; 228 117 122
74. Pearson P. A., Comstock T. L., Ip M. et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology: 2011; 118 1580 1587
75. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol: 2007; 18 235 239 (Pubitemid 46624923)
76. Campochiaro P. A., Brown D. M., Pearson A. et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology: 2012; 119 2125 2132
77. Fachinformation Zulassung für BRD für Iluvien (Zul.-Nr. 82809.00.00). BfArM 2013.
78. Bresnick G. H. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology: 1983; 90 1301 1317 (Pubitemid 14200813)
79. Klaassen I., Van Noorden C. J., Schlingemann R. O. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res: 2013; 34 19 48
80. Early Treatment Diabetic Retinopathy Study research group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol: 1985; 103 1796 1806
81. Early Treatment Diabetic Retinopathy Study research group Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol: 1995; 113 1144 1155
82. Shah A. M., Bressler N. M., Jampol L. M. Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol: 2011; 152 332 339
83. Neubauer A. S., Langer J., Liegl R. et al. Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser. Clin Ophthalmol: 2013; 7 121 128
84. Roider J., Hillenkamp F., Flotte T. et al. Microphotocoagulation: selective effects of repetitive short laser pulses. Proc Natl Acad Sci USA: 1993; 90 8643 8647 (Pubitemid 23277726)
85. Brinkmann R., Roider J., Birngruber R. Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol: 2006; 302 51 69
86. Berger J. W. Thermal modelling of micropulsed diode laser retinal photocoagulation. Lasers Surg Med: 1997; 20 409 415 (Pubitemid 27188112)
87. Wood J. P., Shibeeb O., Plunkett M. et al. Retinal damage profiles and neuronal effects of laser treatment: Comparison of a conventional photocoagulator and a novel, 3-nanosecond pulse laser. Invest Ophthalmol Vis Sci: 2013; 54 2305 2318
88. Chidlow G., Shibeeb O., Plunkett M. et al. Glial cell and inflammatory responses to retinal laser treatment: Comparison of a conventional photocoagulator and a novel, 3-nanosecond pulse laser. Invest Ophthalmol Vis Sci: 2013; 54 2319 2332
89. Puliafito C. A., Deutsch T. F., Boll J. et al. Semiconductor laser endophotocoagulation of the retina. Arch Ophthalmol: 1987; 105 424 427
90. Friberg T. R., Karatza E. C. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmology: 1997; 104 2030 2038 (Pubitemid 28053429)
91. Friberg T. R. Infrared micropulsed laser treatment for diabetic macular edema-subthreshold versus threshold lesions. Semin Ophthalmol: 2001; 16 19 24 (Pubitemid 34132528)
92. Laursen M. L., Moeller F., Sander B. et al. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol: 2004; 88 1173 1179 (Pubitemid 39141379)
93. Luttrull J. K., Musch D. C., Mainster M. A. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol: 2005; 89 74 80 (Pubitemid 40040243)
94. Stanga P. E., Reck A. C., Hamilton A. M. Micropulse laser in the treatment of diabetic macular edema. Semin Ophthalmol: 1999; 14 210 213 (Pubitemid 30061163)
95. Roider J., Brinkmann R., Wirbelauer C. et al. Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol: 2000; 84 40 47 (Pubitemid 30251632)
96. Elsner H., Klatt C., Liew S. H. et al. [Selective retina therapy in patients with diabetic maculopathy]. Ophthalmologe: 2006; 103 856 860 (Pubitemid 44622566)
97. Roider J., Liew S. H., Klatt C. et al. Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol: 2010; 248 1263 1272
98. Steijns D., Duijvesz D., Breedijk M. A. et al. Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol: 2010; 88 389 393
99. Mirshahi A., Shenazandi H., Lashay A. et al. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina: 2010; 30 254 259
100. Elman M. J., Qin H., Aiello L. P. et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology: 2012; 119 2312 2318
101. Ford J. A., Lois N., Royle P. et al. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open: 2013; 3 e002269
102. Beck R. W., Edwards A. R., Aiello L. P. et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol: 2009; 127 245 251
103. Lang G. E., Lang S. J. Clinical treatment of diabetic macular edema. Klin Monbl Augenheilkd: 2011; 228 R1 11